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Background: Documentation of structured quality indicators for mycobacteriology
laboratories supporting exclusively controlled clinical trials in pulmonary tuberculosis
(PTB) is lacking.
Objective: To document laboratory indicators for a solid (Lowenstein–Jensen medium)
culture system in a mycobacteriology laboratory for a period of 4 years (2007–2010).
Methods: The sputum samples, collected from PTB suspects/patients enrolled in clinical
trials, were subjected to fluorescence microscopy, culture and drug sensitivity testing
(DST). Data was retrospectively collected from TB laboratory registers and computed using
pre-formulated Microsoft Office Excel. Laboratory indicators were calculated and analyzed.
Results: The number of samples processed in a calendar year varied from 6261 to 10,710. Of
the samples processed in a calendar year, specimen contamination (4.8–6.9%), culture pos-
itives (78.4–85.1%) among smear positives, smear positives (71.8–79.0%) among culture posi-
tive samples, smear negatives among culture negative samples (95.2–96.7%), and average
time to report DST results (76–97 days) varied as shown in parentheses.
Conclusion: Values of quality indicators in mycobacteriology laboratories supporting exclu-
sively clinical trials of PTB have to be defined and used for meaningful monitoring of
laboratories.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction
The World Health Organization (WHO) declared Tuberculosis
(TB) a global emergency in 1993. Although all efforts are being
made to control the disease in high burden countries, the con-
trol of drug-resistant TB remains a big challenge [1]. The diag-
nosis of drug-resistant TB is achieved by the services rendered
by the solid culture and drug susceptibility testing (DST) labo-
ratories that are being scaled up throughout the world, apart
from other rapid diagnostic methods [2]. The quality of these
laboratory services has to be ensured in order to give maxi--African Society for Myco
2528.
mail.com (N. Selvakumarmum benefits to the patients. The quality indicators for diag-
nostic mycobacteriology laboratories have been recently
suggested by McCarthy et al. [3], and the TB laboratory registers
have been designed to collect such performance indicators.
Efficacies of various treatment regimens for PTB are being
assessed in controlled clinical trials. These controlled clinical
trials are ably supported by mycobacteriology laboratories.
The TB laboratory registers in these mycobacteriology labora-
tories supporting exclusively controlled clinical trials are
presumably not standardized, and each and every laboratory
may have designed their own TB laboratory registers to recordbacteriology. All rights reserved.
).
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bacteriology laboratory indicators, although monitored by the
investigating teams, is not well documented.
The National Institute for Research in Tuberculosis (NIRT),
Chennai, which is a National Reference Laboratory under the
Revised National Tuberculosis Control Program (RNTCP), In-
dia, as well as the Supra-national Reference Laboratory for
the South East Asian region under the World Health Organiza-
tion (WHO) is supporting controlled clinical trials for PTB and
extra-PTB since 1956, and the TB laboratory registers designed
then are being used continuously [4]. In this study, an attempt
is made to compile the information available in TB laboratory
registers in the mycobacteriology laboratory at NIRT support-
ing exclusively controlled clinical trials for 4 years to get some
insight into the quality indicators for sputum AFB microscopy
and culture of Mycobacterium tuberculosis.
Materials and methods
Study subjects
The NIRT conducts controlled clinical trials for pulmonary
tuberculosis (PTB) [5,6]. It investigates new smear-positive
and previously treated PTB patients referred from hospitals
in and around Chennai city for inclusion in clinical trials. It
obtains informed consent from all patients prior to enroll-Table 1 – Distribution of smear and culture results.
Year Smear resultsa Culture resultsb
3+ 2+ 1+ Cols
2007 3+ 69 43 6 0
2+ 213 188 36 8
1+ 170 529 234 94
Any positive 452 760 276 102
NEG 13 163 270 180
Total 465 923 546 282
2008 3+ 69 34 1 0
2+ 214 146 31 15
1+ 179 429 313 103
Any positive 462 609 345 118
NEG 10 86 177 143
Total 472 695 522 261
2009 3+ 44 34 3 0
2+ 121 155 44 13
1+ 86 299 196 91
Any positive 251 488 243 104
NEG 3 50 196 102
Total 254 538 439 206
2010 3+ 29 12 4 1
2+ 144 119 40 15
1+ 77 216 196 78
Any positive 250 347 240 94
NEG 10 25 117 95
Total 260 372 357 189
a 1+ = 4 AFB in at least 50 fields or <5 AFB/field in at least 50 fields; 2+ = 5–
b Cols = 1–19 colonies; 1+ = 20–100 colonies; 2+ = innumerable colonies; 3+ment into the studies. Studies conducted by the NIRT are ap-
proved by the Institutional Ethics Committee.
Sample collection and processing
Sputum specimens, both spot (S) and early morning home
collection (H) in about 5 ml, were collected from all regis-
tered patients. Four sputum samples viz. two ‘‘S’’ and two
‘‘H’’, were collected from all patients before initiating treat-
ment; one ‘‘S’’ and two ‘‘H’’ samples were collected from pa-
tients during the treatment period and one ‘‘H’’ and one ‘‘S’’
were collected once in 3 months from patients during the
follow-up period ranging from 2 to 5 years depending on
the study. The sputum samples, with occasional exceptions,
were processed on the same day or on the next working day.
Their direct smears were subjected to fluorescence micros-
copy and were processed by modified Petroff’s method for
culture by standard operating procedures followed at the
NIRT [7]. Processed deposits were inoculated onto two of
Lowenstein–Jensen (LJ) medium and cultures were incubated
at 37 C. A weekly growth reading was taken for 8 weeks and
culture grading was recorded. Biochemical tests, such as nia-
cin and catalase tests, and growth on para-nitrobenzoic acid
were performed to confirm M. tuberculosis was isolated. The
date on which DST was set up got noted against the culture
selected for testing.Any positive NEG Cont NTM TOTAL
118 2 2 0 122
445 16 5 9 475
1027 183 11 50 1271
1590 201 18 59 1868
626 7551 191 474 8842
2216 7752 209 533 10710
104 5 0 0 109
406 21 10 5 442
1024 258 20 29 1331
1534 284 30 34 1882
416 6445 143 310 7314
1950 6729 173 344 9196
81 2 0 0 83
333 13 3 1 350
672 206 12 20 910
1086 221 15 21 1343
351 5017 108 305 5781
1437 5238 123 326 8467
46 4 2 0 52
318 39 0 3 360
567 187 2 19 775
931 230 4 22 1187
247 4555 42 230 5074
1178 4785 46 252 6261
100 AFB per field: 3+ = >100 AFB per field.
= confluent growth.
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Once the culture results (M. tuberculosis, contamination with
bacteria, and contamination with NTM) were recorded by
the laboratory personnel in registers, all the details of the
specimens in the registers were transferred immediately,
again with occasional exceptions, to the patients’ case sheets
for clinical management.
The following information for each specimen was col-
lected from the registers: laboratory number, smear and cul-
ture results, and the dates on which DST was set up and
reported. The data was entered in pre-formulated Microsoft
Office Excel program. The laboratory performance indicators,
such as percentages of specimen contaminated with bacteria
and NTM among samples processed in a calendar year, cul-
ture positivity among smear positive samples, smear negativ-
ity among culture-negative samples and average turnaround
time (from the date of collection of the sample until the
DST results were reported) were calculated and analyzed as
suggested by McCarthy et al. [3].
Results
Table 1 shows the details of the samples received and the dis-
tribution of smear results against their corresponding culture
results. A total number of 34,634 samples were processed. The
maximum number received was in the year 2007 and there
was a gradual decline in the number of samples received in
the subsequent years.
The performance of quality indicators for a period of
4 years (2007–2010) in the mycobacteriology laboratory are gi-
ven in Table 2. The overall contaminated samples among the
total samples processed in a year varied from 4.7% to 6.9%.
Among the total contaminated, the specimen contaminated
with bacteria (15.4–33.5%) and the specimen contaminated
with NTM (66.5–84.6%) varied as shown in parenthesis. Cul-
ture-positives among smear-positive samples (rate of recov-
ery) ranged between 78.4% and 85.1%. Smear-positives
among culture-positive samples (sensitivity of microscopy)
varied from 71.7% to 79.0% and smear-negatives among cul-
ture-negative samples (specificity of microscopy) varied from
95.2% to 97.4%. Average turnaround time for doing DST ran-
ged from 76 to 97 days.
Discussion
During the study period, there was a decline in the number of
samples processed during a calendar year. This was due to
the decline in the number of patients referred from health
posts in and around Chennai city for assessment to enroll
in clinical trials: 2007 – 342; 2008 – 279; 2009 – 254; and 2010
– 83.
In the study, the recovery of M. tuberculosis from smear-
positive samples varied from 78.4% to 85.1%. The reduced
recovery from smear-positive samples, as observed in the
present data analysis, could be attributed to the inclusion of
diagnostic and follow-up samples. In the TB laboratory regis-
ter, the information concerning whether the sample is for
diagnostic or for follow-up examination is not recorded in or-
der to avoid bias in investigations. Moreover, the diagnostic
188 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 1 ( 2 0 1 2 ) 1 8 5 –1 8 9samples in the study include those from patients who were
assessed and excluded for several reasons, including the his-
tory of previous treatment for more than a month. It is to be
pointed out that the proportion of smear-positive samples
yielding culture-positive results is known to be reduced in
patients currently being treated [8,9]. It is also known that,
in patients receiving a rifampicin-containing regimen, around
20–25% of smear-positive samples can yield culture-negative
results in samples collected during the follow-up period [10].
The sensitivity of microscopy varied from 71.7% to 79.0%.
The reduced sensitivity of microscopy was again as a result
of the inclusion of diagnostic and follow-up sputum samples
from clinical trials. In a separate study conducted at the NIRT,
the sensitivity of microscopy for diagnostic and follow-up
samples for the same cohort of patients in a clinical trial
respectively was found to be 95.0% and 60.0% [11]. However,
this information was obtained from specially designed cul-
ture cards for individual patients.
The specimen contamination rate among the total sam-
ples processed ranged between 4.7% and 6.9% during the
study period. The rate of contamination with NTM among
the total contaminated samples varied from 66.5% to 84.6%.
NTM could be environmental or laboratory contaminants,
although their probable recovery from sputum samples can-
not be ruled out. Unless NTM is recovered from the same pa-
tient in multiple samples and with heavy growth, it cannot be
considered as atypical mycobacteriosis, and also this status
cannot be ascertained from the TB laboratory registers unless
efforts are taken to sort the data based on each patient [12].
The contamination with NTM among the total samples varied
from 3.7% to 5.0%. It was reported from this laboratory that as
much as 8–10% of sputum samples, collected from patients in
TB surveys in epidemiological studies carried out in the Thir-
uvallur area, which is 40 kilometers away from the present
study area, yielded NTM [13]. The low recovery of NTM in
the study suggests that NTM is not common in the controlled
clinical study area, or it could be due to selective populations
studied.
Turnaround time (TAT) for MIC method is 70 days (6 weeks
for culture isolation and 4 weeks for DST). The average TAT
for DST varied between 76 and 97 days. The delay in TAT in
2007 and 2008 could be owing to a large number of cultures
selected and batched for DST in the laboratory. It improved
over the years when the sample load decreased. It should be
mentioned that cultures from diagnostic samples and from
relapses were subjected to DST on priority. The cultures from
follow-up samples were batched and DST was set up.
In the present analysis, performance indicators reveal the
quality of laboratory processes. McCarthy et al. (2008) [3] ear-
lier collected the data from four regional and national TB
reference laboratories in Bangkok, Thailand, and analyzed
the data using the set of indicators mentioned above. McCar-
thy’s mycobacteriology laboratory performance indicator
scheme is used, for the first time, to know its relevance for
the data collected from standard smear and culture registers
maintained in a mycobacteriology laboratory supporting
controlled clinical trials of PTB. The indicator values provide
an insight, for the first time into the performance of a myco-
bacteriology laboratory supporting exclusively clinical trials
for PTB.Conclusion
The findings of this study provide meaningful mycobacteriol-
ogy laboratory performance indicators that can be defined
and used to monitor the quality of laboratories supporting
exclusively the controlled clinical trials in pulmonary
tuberculosis.
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